Abstract
We are evaluating strategies to enhance the in vivo proliferation and function of adoptively transferred antigen-specific T cells. Although the CD28 costimulatory pathway is important for T cell activation and proliferation, the expression of the ligands for CD28 is highly restricted. We have generated a chimeric receptor composed of the signaling domains of CD28 and the extracellular domain of CD2 which binds the widely expressed ligand CD58. The CD2/CD28 chimeric receptor was introduced into CTLL.2 cells via retrovirus infection and was shown to be expressed on the cell surface. By monitoring early and late components of the CD28 signaling pathway, the chimeric receptor was demonstrated to trigger the CD28 pathway in response to CD2 cross-linking. The possible utility of the CD2/CD28 chimeric receptor for adoptive immunotherapy is discussed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feldhaus, A., Evans, L., Sutherland, R. et al. A CD2/CD28 chimeric receptor triggers the CD28 signaling pathway in CTLL.2 cells. Gene Ther 4, 833–838 (1997). https://doi.org/10.1038/sj.gt.3300456
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300456
Keywords
This article is cited by
-
A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function
Journal for ImmunoTherapy of Cancer (2019)